Anti-IL-17A/IL-17F cross-reactive antibodies

  • US 8,715,669 B2
  • Filed: 12/28/2011
  • Issued: 05/06/2014
  • Est. Priority Date: 05/05/2008
  • Status: Active Grant
First Claim
Patent Images

1. An isolated antibody, or an antigen-binding fragment thereof, that (1) binds IL-17A homodimer, IL-17F homodimer and IL-17A/IL-17F heterodimeric complex, and (2) exhibits (i) a binding affinity of at least 100 pM or less against the human IL-17A homodimer, (ii) a binding affinity of at least 300 pM or less against the human IL-17F homodimer, (iii) a binding affinity of at least 400 pM or less against the human IL-17A/IL-17F heterodimeric complex, (iv) a neutralizing ability of at least 40 nM or less against the human IL-17A homodimer, (v) a neutralizing ability of at least 120 nM or less against the human IL-17F homodimer, and (vi) a neutralizing ability of at least 31 nM or less against the human IL-17A/IL-17F heterodimeric complex, wherein the binding affinity is measured by surface plasmon resonance, and the neutralizing ability is determined by measuring IL-6 secretion by IL-17A, IL-17F or IL-17A/IL-17F heterodimeric complex-stimulated mouse or human embryonic fibroblasts.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×